IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.
Size
Various Sizes
Concentration
n/a
Applications
Cell Culture
Other Names
Insulin-like growth factor-binding protein 7;IBP-7;IGF-binding protein 7;IGFBP-7;IGFBP-rP1;MAC25 protein;PGI2-stimulating factor;Prostacyclin-stimulating factor;Tumor-derived adhesion factor;TAF;IGFBP7;MAC25, PSF; Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)